Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This situation generates substantial inefficiencies with many scanners being ...

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly ...

Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may ...

Radiopharmaceutical therapy (RPT) is entering a new era of personalization, driven by advances in molecular imaging, radiopharmaceutical development, and a growing body of clinical evidence linking ...

We propose strongly unrealistic data augmentation to improve the robustness of convolutional neural networks (CNNs) for automatic classification of dopamine transporter SPECT against the variability ...

Digital PET/CT systems with a long axial field of view have become available and are emerging as the current state of the art. These new camera systems provide wider anatomic coverage, leading to ...

The impact of PET image acquisition and reconstruction parameters on SUV measurements or radiomic feature values is widely documented. This scanner effect is detrimental to the design and validation ...

Owen Witte, MD, is recognized for multiple seminal contributions over the past 50 years impacting our understanding of human leukemias, immune disorders, and epithelial cancers, which have defined new ...

MULTIORGAN ANALYSIS WITH STANDARD WB PET Traditional WB PET with an axial FOV of about 20 cm can already be used for multiorgan analysis. For example, simple intergroup comparisons of organ-based SUV ...

Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine MIRD Pamphlet No. 28, Part ...

Radiopharmaceutical therapy is growing rapidly. However, yet to be addressed is the implementation of methods to plan treatments for circulating tumor cells, disseminated tumor cells, and ...

Prostate-specific membrane antigen (PSMA)–targeting radiopharmaceuticals, such as the novel [177Lu]Lu-HTK03170, present a promising therapeutic option for metastatic castration-resistant prostate ...